Dr. Oliver Dorigo, MD, PHD
Gynecologic Oncologist
,Reproductive Endocrinologist
,Obstetrician
,Obstetrician / Gynecologist (OBGYN)
Stanford, CA
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Dorigo, Gynecologic Oncologist in Stanford, CA?
Dr. Oliver Dorigo, MD, PHD is a Gynecologic Oncologist, who primarily practices in Stanford, CA with 2 additional practice locations. He is board certified by the American Board of Obstetrics and Gynecology. Dr. Dorigo completed his residency at Ucla Med Ctr/Ucla D Geffen Sch, Obstetrics And Gynecology. Dr. Dorigo is fluent in English, French, German, and Italian, and is currently seeing new patients. Dr. Dorigo’s practice accepts Kaiser Permanente, Medicaid, Medicare, UnitedHealthcare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Dorigo’s office at (650) 723-4000.
Where did Dr. Dorigo go to medical school and complete their residency?
Fellowship: UCLA School of Medicine, Los Angeles, CA | UCLA School of Medicine CA | UCLA
Residency: Ucla Med Ctr/Ucla D Geffen Sch, Obstetrics And Gynecology | UCLA School of Medicine
Medical School: Ruprecht-Karl-Univ- Med Fak- Heidelberg- Germany
Is Dr. Dorigo board certified in Gynecologic Oncologist?
Yes, Dr. Oliver Dorigo, MD, PHD is board certified by the American Board of Obstetrics and Gynecology , American Board of Obstetrics and Gynecology since 2008, American Board of Obstetrics and Gynecology since 2006
What languages does Dr. Dorigo speak?
Dr. Dorigo and their clinical team can communicate with patients in the following languages:
English
French
German
Italian
What conditions does Dr. Dorigo treat?
As a Gynecologic Oncologist, Dr. Dorigo diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Dorigo. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly.
Also known as:
- Ovarian Cancer
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
- Cancer of the ovary
- Ovarian carcinoma
- Female reproductive cancer
ICD-10 Codes:
- C569: Malignant neoplasm of unspecified ovary
- C562: Malignant neoplasm of left ovary
- C561: Malignant neoplasm of right ovary
- C563: Malignant neoplasm of bilateral ovaries
Also known as:
- Endometrial Cancer
- Uterine Cancer
- Endometrial Cancer Treatment (PDQ®)
- Endometrial Cancer Treatment (PDQ)
- Malignant Endometrial Tumor
- Endometrial Carcinoma
- Cancer of the Endometrium
- Malignant Uterine Tumor
- Uterine Carcinoma
- Cancer of the Uterus
- Womb cancer
- Endometrial cancer
- Uterine carcinoma
ICD-10 Codes:
- C541: Malignant neoplasm of endometrium
- C55: Malignant neoplasm of uterus, part unspecified
- C549: Malignant neoplasm of corpus uteri, unspecified
Also known as:
- Cervical Cancer
- Early Cervical Cancer
- Malignant Cervical Tumor
- Cervical Carcinoma
- Cancer of the Cervix
- Carcinoma in situ of cervix
- Precancerous cervical cells
- Non-invasive cervical cancer
- Stage 0 cervical cancer
ICD-10 Codes:
- C539: Malignant neoplasm of cervix uteri, unspecified
- D069: Carcinoma in situ of cervix, unspecified
Also known as:
- Abdominal or Pelvic Swelling, Mass, or Lump
- Belly lump
- Pelvic mass
- Abdominal swelling
ICD-10 Codes:
- R1900: Intra-abdominal and pelvic swelling, mass and lump, unspecified site
Also known as:
- Growth of Unknown Type in the Ovary
- Ovarian Disorder
- Indeterminate ovarian mass
- Ovarian tumor of unknown nature
- Ovarian neoplasm of uncertain behavior
ICD-10 Codes:
- D3910: Neoplasm of uncertain behavior of unspecified ovary
Also known as:
- Vulvar Cancer
- Cancer of the vulva
- Vulvar carcinoma
- External female genital cancer
ICD-10 Codes:
- C519: Malignant neoplasm of vulva, unspecified
Also known as:
- Fallopian Tube Cancer
- Uterine Cancer
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)
- Malignant Fallopian Tube Tumor
- Fallopian Tube Carcinoma
ICD-10 Codes:
- C5700: Malignant neoplasm of unspecified fallopian tube
Also known as:
- Cancer Chemotherapy
- Chemo treatment
- Oncology chemotherapy
- Cancer drug therapy
ICD-10 Codes:
- Z5111: Encounter for antineoplastic chemotherapy
Also known as:
- Peritoneal Cancer
- Cancer
- Peritoneal Disorder
- Cancer of Peritoneum
- Abdominal Lining Cancer
- Primary Peritoneal Cancer
- Peritoneal Carcinomatosis
ICD-10 Codes:
- C482: Malignant neoplasm of peritoneum, unspecified
Also known as:
- Endometrial Intraepithelial Neoplasia
- Uterine Disease
- EIN
- Precancerous Uterine Cells
- Atypical Endometrial Hyperplasia
ICD-10 Codes:
- N8502: Endometrial intraepithelial neoplasia [EIN]
Also known as:
- Other Female Genital and Menstrual Condition
- Menstruation
- Vaginal Disease
- Vulvar Disorder
- Specific Gynecological Conditions
- Menstrual Cycle Problems
ICD-10 Codes:
- N9489: Other specified conditions associated with female genital organs and menstrual cycle
Also known as:
- Fallopian Tube Cancer
- Uterine Cancer
- Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ)
- Fallopian tube carcinoma
- Gynecologic cancer
ICD-10 Codes:
- C5701: Malignant neoplasm of right fallopian tube
Also known as:
- Genetic Susceptibility to Breast Cancer
- Breast cancer
- Li-Fraumeni syndrome
- Inherited Breast Cancer Risk
- Hereditary Breast Cancer
- BRCA Gene Mutation
ICD-10 Codes:
- Z1501: Genetic susceptibility to malignant neoplasm of breast
Also known as:
- Right Ovarian Cyst
- Ovarian Cysts
- Benign right ovarian tumor
- Right ovarian mass
- Non-cancerous right ovarian growth
ICD-10 Codes:
- D270: Benign neoplasm of right ovary
Which procedures does Dr. Dorigo perform as a Gynecologic Oncologist?
As a Gynecologic Oncologist, procedures performed by a Dr. Oliver Dorigo may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
For detailed information, please contact Dr. Dorigo's office.
Does Dr. Dorigo accept my insurance?
Dr. Dorigo accepts most major insurance plans. Important: Please call our office at (650) 723-4000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Dorigo accept in Stanford, CA?
Dr. Dorigo in Stanford, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
AllCare Health Plan
Blue Shield of California
Centene
Central California Alliance for Health
CVS Health (formerly Aetna)
Medicaid
Medicare
State of California
UnitedHealthcare
View All Insurances
Where is Dr. Dorigo's office located?
Recognitions
Awards
Southern California Super Doctors
OB/GYN Resident Teaching Award,
STOP Cancer Career Development Award, STOP Cancer
Teaching Award, National Council on Resident Education in Obstetrics
Outstanding Podium Presentation Award
National Gynecologic Oncology Fellow's Forum
American Association of Cancer Research Outstanding Poster Award, Tor
Publications
Increased risk and pattern of secondary maligncies in patients with invasive extramammary Paget
British jourl of dermatology, 2014
MMPs in Ovarian Cancer as Therapeutic Targets
ANTI-CANCER AGENTS IN MEDICIL CHEMISTRY, 2012
Correlative nomechanical profiling with super-resolution F
NOMEDICINE-NOTECHNOLOGY BIOLOGY AND MEDICINE, 2012
Persolizing CA125 Levels for Ovarian Cancer Screening
CANCER PREVENTION RESEARCH, 2011
Cisplatin and PI3kise Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells
CYTOSKELETON, 2010
Robust In Vivo Transduction of a Genetically Stable Epstein
JOURL OF VIROLOGY, 2009
Dual targeting of mammalian target of rapamycin
GYNECOLOGIC ONCOLOGY, 2009
Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient
AMERICAN JOURL OF TRANSPLANTATION, 2009
Enhanced Expression of L9'S Mutant ChR
The Jourl of the Federation of American Societies for Experimental Bio, 2006
Development of a novel helper-dependent adenovirus
JOURL OF VIROLOGY, 2004
Enhanced expression of L9'S mutant alpha 4 ChR
MOVEMENT DISORDERS, 2004
A radical debulking of leiomyomatosis peritonealis dissemita from a colonic obstruction
JOURL OF THE AMERICAN COLLEGE OF SURGEONS, 2000
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites
JOURL OF IMMUNOLOGY, 1999
Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild
JOURL OF NEUROSURGERY, 1998
Gene therapy for ovarian cancer ? Molecular scissors of the new millenium?
Jourl of Gynecologic Techniques, 1998
Construction and characterization of retroviral vectors for interleukin-2 gene therapy
JOURL OF IMMUNOTHERAPY, 1997
Gene therapy for ovarian cancer: Development of novel treatment strategies
INTERTIOL JOURL OF GYNECOLOGICAL CANCER, 1997
Eradication of established intracranial rat gliom
PROCEEDINGS OF THE TIOL ACADEMY OF SCIENCES OF THE UNITED STATES OF AM, 1996
COMPARISON OF GENE-THERAPY WITH INTERLEUKIN
JOURL OF IMMUNOTHERAPY, 1995
LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNT
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993
ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM
EUROPEAN HEART JOURL, 1993
A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNCIES IN AIDS
HYBRIDOMA, 1993
A MONOCLOL-ANTIBODY
JOURL OF CELLULAR BIOCHEMISTRY, 1993
NEW TECHNIQUES FOR THE STUDY OF THE CORORY MICROCIRCULATION
CORORY ARTERY DISEASE, 1992
SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS
JOURL OF PERITAL MEDICINE, 1992
PHARMACOLOGICAL EFFECTS ON CORORY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA
EUROPEAN HEART JOURL, 1990
MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART
EUROPEAN JOURL OF CLINICAL PHARMACOLOGY, 1990
Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget
British journal of dermatology, 2014
Anti-N-methyl-aspartate receptor encephalitis in identical twin sisters: role for oophorectomy.
Obstetrics and gynecology, 2014
MMPs in Ovarian Cancer as Therapeutic Targets
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2012
Solid pseudopapillary neoplasm, pancreas type, presenting as a primary ovarian neoplasm
HUMAN PATHOLOGY, 2012
Expression of thyroid transcription factor
MODERN PATHOLOGY, 2012
Correlative nanomechanical profiling with super-resolution F
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2012
Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease
GYNECOLOGIC ONCOLOGY, 2012
Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma
GYNECOLOGIC ONCOLOGY, 2012
Effect of PI3K/Akt Pathway Inhibition
ANTICANCER RESEARCH, 2012
Personalizing CA125 Levels for Ovarian Cancer Screening
CANCER PREVENTION RESEARCH, 2011
Cisplatin and PI3kinase Inhibition Decrease Invasion and Migration of Human Ovarian Carcinoma Cells
CYTOSKELETON, 2010
Robust In Vivo Transduction of a Genetically Stable Epstein
JOURNAL OF VIROLOGY, 2009
Dual targeting of mammalian target of rapamycin
GYNECOLOGIC ONCOLOGY, 2009
Death from Metastatic Donor-Derived Ovarian Cancer in a Male Kidney Transplant Recipient
AMERICAN JOURNAL OF TRANSPLANTATION, 2009
HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
GYNECOLOGIC ONCOLOGY, 2008
CA125: Megadaltons of novel opportunities
GYNECOLOGIC ONCOLOGY, 2007
Enhanced Expression of L9'S Mutant nAChR
The Journal of the Federation of American Societies for Experimental B, 2006
Development of a novel helper-dependent adenovirus
JOURNAL OF VIROLOGY, 2004
Enhanced expression of L9'S mutant alpha 4 nAChR
MOVEMENT DISORDERS, 2004
Specific keynote: Immunological therapy for ovarian cancer
GYNECOLOGIC ONCOLOGY, 2003
Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002
A radical debulking of leiomyomatosis peritonealis disseminata from a colonic obstruction
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2000
IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites
JOURNAL OF IMMUNOLOGY, 1999
Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild
JOURNAL OF NEUROSURGERY, 1998
Gene therapy for ovarian cancer ? Molecular scissors of the new millenium?
Journal of Gynecologic Techniques, 1998
Synergy of transforming growth factor beta
Gynecologic Oncology, 1998
Progress and prospects in vaccine therapy for gynecologic cancers.
Oncology (Williston Park, N.Y.), 1997
Construction and characterization of retroviral vectors for interleukin-2 gene therapy
JOURNAL OF IMMUNOTHERAPY, 1997
Gene therapy for ovarian cancer: Development of novel treatment strategies
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1997
Interleukin-2 (IL-2) gene therapy with allogenic fibroblasts in the CT-26 model of murine
Oncology Reports, 1997
Eradication of established intracranial rat gliom
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O, 1996
Immuno-gene therapy of colon carcinoma and central nervous tumors
In: Gene Therapy and Cancer
COMPARISON OF GENE-THERAPY WITH INTERLEUKIN
JOURNAL OF IMMUNOTHERAPY, 1995
INTERLEUKIN-2 GENE-THERAPY IN A PATIENT WITH GLIOBLASTOMA
GENE THERAPY, 1995
CHARACTERIZATION OF A NEW HUMAN GLIOBLASTOMA CELL
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 1995
INJECTION OF COLON-CARCINOMA PATIENTS WITH AUTOLOGOUS IRRADIATED TUMOR
HUMAN GENE THERAPY, 1995
Apoptosis of CD4+ and CD8+ cells from HIV-1 infected individuals: role of anti-idiotypic antibodies
Vaccine Research, 1995
VALUE OF BOWEL RESECTION AND PREOPERATIVE COLOSCOPY IN OVARIAN-CANCER
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993
LYMPHOCYTE SUBPOPULATIONS IN WOMEN WITH MALIGNANT
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993
ACTIVATION OF NEUTROPHILS IN THE MICROVASCULATURE OF THE ISCHEMIC AND REPERFUSED MYOCARDIUM
EUROPEAN HEART JOURNAL, 1993
A NON-LYMPHOMA IDIOTYPE IS INDICATIVE AND PREDICTIVE FOR B-CELL MALIGNANCIES IN AIDS
HYBRIDOMA, 1993
A MONOCLONAL-ANTIBODY
JOURNAL OF CELLULAR BIOCHEMISTRY, 1993
NEW TECHNIQUES FOR THE STUDY OF THE CORONARY MICROCIRCULATION
CORONARY ARTERY DISEASE, 1992
SHORT-TERM OUTCOME IN INFANTS WITH BIRTH WEIGHTS LESS
JOURNAL OF PERINATAL MEDICINE, 1992
PHARMACOLOGICAL EFFECTS ON CORONARY MICROVESSELS DURING MYOCARDIAL-ISCHEMIA
EUROPEAN HEART JOURNAL, 1990
MICROCIRCULATION IN THE HYPERTROPHIC AND ISCHEMIC HEART
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990
What is Dr. Dorigo's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Dorigo's National Provider Identifier (NPI) number is 1306873294.
What common questions do patients ask about Dr. Dorigo?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Dorigo
What is Dr. Oliver Dorigo's specialty?
Dr. Dorigo is a Gynecologic Oncologist near Stanford, CA. An obstetrician/gynecologist specializing in gynecologic oncology provides consultation and comprehensive management for patients with gynecologic cancer. This includes performing diagnostic and therapeutic procedures essential for the total care of patients with gynecologic cancer and addressing any resulting complications. Contact Dr. Dorigo to book an appointment today.
Is this Dr. Oliver Dorigo affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Dorigo is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
Where can I learn more about Gynecologic Oncologist?
Explore Gynecologic Oncologist with insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Oliver Dorigo accepting new patients in Stanford, CA?
Yes, Dr. Oliver Dorigo is accepting new patients at this time.
Does Dr. Oliver Dorigo offer online booking?
Please contact Dr. Dorigo's office at (650) 723-4000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Oliver Dorigo?
Please contact Dr. Dorigo's office at (650) 723-4000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Oliver Dorigo have?
Dr. Oliver Dorigo is certified by the American Board of Obstetrics and Gynecology.
Other Gynecologic Oncologist Near Stanford, CA
Gynecologic Oncologist
Accepting patientsGynecologic Oncologist
Accepting patients
Gynecologic Oncologist
Accepting patients